C14orf44 Inhibitors
Chemical inhibitors of C14orf44 function through various mechanisms to inhibit its activity. Palbociclib, by inhibiting CDK4 and CDK6, can suppress C14orf44 if it is phosphorylated by these kinases, which is a common regulatory mechanism for protein function. Similarly, Dasatinib can inhibit C14orf44 by targeting BCR-ABL and Src family kinases, which may phosphorylate C14orf44. The PI3K inhibitors, LY294002 and Wortmannin, can disrupt PI3K-dependent signaling pathways that C14orf44 may be involved in, leading to a decrease in its activity. U0126 and PD98059, both selective inhibitors of MEK1/2 within the MAPK/ERK pathway, can inhibit C14orf44 if it is a downstream effector in this pathway. SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, can suppress C14orf44's function if it relies on these pathways for activation or stability.
Furthermore, Trichostatin A, an HDAC inhibitor, can alter gene expression and protein function by preventing deacetylation, which could inhibit C14orf44 if it is regulated by acetylation. Proteasome inhibitors such as Bortezomib and MG132 can lead to the accumulation of non-functional C14orf44 or its substrates by blocking proteasomal degradation, which could result in functional inhibition. Kinase inhibitors such as ZM-447439, PF-562271, Imatinib, Lapatinib, Sorafenib, Sunitinib, Erlotinib, and Gefitinib target a variety of kinases and can inhibit C14orf44 if its activity depends on signals from the kinases they inhibit. For example, ZM-447439 targets Aurora kinases that are crucial for cell cycle progression, and PF-562271 inhibits FAK/Pyk2, which may affect C14orf44 if it is part of focal adhesion signaling. Imatinib, Lapatinib, Sorafenib, Sunitinib, Erlotinib, and Gefitinib inhibit tyrosine kinases involved in growth factor signaling, and can thus inhibit C14orf44 if it functions downstream of these pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Since C14orf44 is a protein, it may require phosphorylation by CDKs for its function or stabilization. Inhibition of CDK4/6 by Palbociclib could lead to reduced phosphorylation of C14orf44, thereby inhibiting its function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). It alters chromatin structure and affects gene expression. If the activity of C14orf44 is regulated by acetylation, Trichostatin A could inhibit its function by maintaining hyperacetylated lysine residues, thus preventing the deacetylation that might be necessary for C14orf44's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. If C14orf44 is involved in a pathway downstream of mTOR, its inhibition by Rapamycin could lead to a decrease in C14orf44's functional activity due to the disruption of mTOR signaling which may be critical for C14orf44's activity or stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. If C14orf44 functions downstream of PI3K or is regulated by PI3K-dependent signaling, LY294002 would inhibit this pathway, potentially leading to reduced activity of C14orf44 as a consequence of inhibited PI3K signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, enzymes in the MAPK/ERK pathway. Inhibition of this pathway by U0126 could result in the inhibition of C14orf44 if the protein’s function is dependent on the MAPK/ERK signaling cascade, as it would prevent the activation of downstream proteins that may be required for C14orf44's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of the p38 MAPK pathway can lead to the functional inhibition of C14orf44 if it operates as part of this signaling cascade or if p38 MAPK-dependent phosphorylation is required for its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, Wortmannin could decrease the activity of C14orf44 if the protein is involved in PI3K-mediated signaling pathways, as it would prevent PI3K-dependent processes that might be essential for the function of C14orf44. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum kinase inhibitor with activity against BCR-ABL and Src family kinases. If C14orf44 relies on phosphorylation by these kinases for its function, inhibition by Dasatinib could lead to reduced activity of C14orf44 due to the blockade of its phosphorylation. | ||||||